On May 3, 2010
Why the Prostate-Cancer Vaccine Provenge Will Do Just Fine in the Real World
Here’s why Dendreon’s (DNDN) newly approved prostate cancer vaccine Provenge will pass the real-world test of commercial success.
No tags for this post.
0 Comments